KALA BIO, Inc. (KALA)
(Delayed Data from NSDQ)
$6.91 USD
+0.20 (2.98%)
Updated May 10, 2024 01:05 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Earnings News For KALA
-
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-
KALA BIO (KALA) Reports Q3 Loss, Misses Revenue Estimates
-
KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update
-
KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update
-
Kala Pharma: Q1 Earnings Snapshot
-
Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
-
Kala Pharma: Q4 Earnings Snapshot
-
Kala Pharma: Q4 Earnings Snapshot
-
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
-
Kala Pharma: Q3 Earnings Snapshot
-
Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-
Kala Pharma: Q2 Earnings Snapshot
-
Kala Pharmaceuticals (KALA) Reports Q2 Loss, Misses Revenue Estimates
-
Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-
Kala Pharmaceuticals (KALA) Reports Q1 Loss, Misses Revenue Estimates
-
Kala Pharmaceuticals (KALA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
-
Kala Pharmaceuticals (KALA) Reports Q4 Loss, Lags Revenue Estimates
-
Will Kala Pharmaceuticals (KALA) Report Negative Q4 Earnings? What You Should Know
-
Kala Pharmaceuticals (KALA) Reports Q3 Loss, Misses Revenue Estimates
-
Kala Pharmaceuticals (KALA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
-
Earnings Preview: Kala Pharmaceuticals (KALA) Q2 Earnings Expected to Decline
-
Kala Pharmaceuticals (KALA) Reports Q1 Loss, Misses Revenue Estimates
-
Kala Pharmaceuticals (KALA) Reports Q4 Loss, Lags Revenue Estimates
-
Kala Pharmaceuticals (KALA) Expected to Beat Earnings Estimates: Should You Buy?
-
Kala Pharmaceuticals (KALA) Reports Q3 Loss, Tops Revenue Estimates